Safety and efficacy of glivec prior to allografting for CML and Ph-positive ALL: European experience

被引：0
|
作者：
Deininger, MWN
Schleuning, M
Olavarria, E
Fischer, T
Nagler, A
Sayer, H
Boque, C
Volin, L
Piotelli, G
Russel, N
Wandt, H
Schanz, U
Greinix, H
Sponk, L
Sponk
Verdonck, L
Lennard, A
Wimmer, M
Hegenbart, U
Lange, T
Niederwieser, D
机构：
来源：
BONE MARROW TRANSPLANTATION | 2002年 / 29卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
183
引用
收藏
页码：S31 / S31
页数：1
相关论文
共 50 条
  • [21] Efficacy and safety of imatinib mesylate (Glivec™) in combination with interferon-α (IFN-α) in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL)
    Wassmann, B
    Scheuring, U
    Pfeifer, H
    Binckebanck, A
    Käbisch, A
    Lübbert, M
    Leimer, L
    Gschaidmeier, H
    Hoelzer, D
    Ottmann, OG
    LEUKEMIA, 2003, 17 (10) : 1919 - 1924
  • [22] CHROMOSOME CHANGES AND SPLENECTOMY IN PH-POSITIVE CML .3. PREDICTIVE PARAMETERS IN THE CHRONIC PHASE
    SADAMORI, N
    SANDBERG, AA
    CANCER GENETICS AND CYTOGENETICS, 1985, 14 (3-4) : 227 - 234
  • [23] Efficacy and safety of imatinib mesylate (Glivec™) in combination with interferon-α (IFN-α) in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL)
    B Wassmann
    U Scheuring
    H Pfeifer
    A Binckebanck
    A Käbisch
    M Lübbert
    L Leimer
    H Gschaidmeier
    D Hoelzer
    O G Ottmann
    Leukemia, 2003, 17 : 1919 - 1924
  • [24] TRANSLOCATION [3-21] IN CHRONIC PHASE OF PH-POSITIVE CHRONIC MYELOGENOUS LEUKEMIA [CML]
    COYLE, T
    NAJFELD, V
    CYTOGENETICS AND CELL GENETICS, 1987, 46 (1-4): : 600 - 600
  • [25] Is autologous HSCT a curative option for Ph-positive ALL with negative MRD status? A survey of the European Working Group for Adult ALL (EWALL)
    Giebel, S.
    Dombret, H.
    Rousselot, P.
    Ribera, J. M.
    Piccaluga, P. P.
    Doubek, M.
    Piatkowska-Jakubas, B.
    Holowiecki, J.
    Hoelzer, D.
    BONE MARROW TRANSPLANTATION, 2010, 45 : S84 - S84
  • [26] BLINATUMOMAB WITH DASATINIB AND INTRATHECAL THERAPY FOR RELAPSED PH-POSITIVE ALL WITH CNS RELAPSE
    Zembillas, Anthony
    Bielek, Kathy
    Mathanda, Reema
    Stanton, Michael
    Rotz, Seth
    PEDIATRIC BLOOD & CANCER, 2021, 68 : S141 - S142
  • [27] Dasatinib and dexamethasone followed by hematopoietic cell transplantation for adults with Ph-positive ALL
    Wieduwilt, Matthew J.
    Yin, Jun
    Wetzler, Meir
    Uy, Geoffrey L.
    Powell, Bayard L.
    Kolitz, Jonathan E.
    Liedtke, Michaela
    Stock, Wendy
    Beumer, Jan H.
    Mattison, Ryan J.
    Storrick, Elizabeth
    Christner, Susan M.
    Lewis, Lionel D.
    Devine, Steven
    Stone, Richard M.
    Larson, Richard A.
    BLOOD ADVANCES, 2021, 5 (22) : 4691 - 4700
  • [28] Ph-positive ALL: will we still need chemotherapy and stem cell transplantion?
    Foa, Robin
    LEUKEMIA RESEARCH, 2018, 73 : S5 - S6
  • [29] Influence of antecedent Glivec® therapy (imatinib mesylate) on allogeneic stem cell transplantation outcome in CML Ph+ and ALL Ph+ patients -: single-centre experience
    Holowiecki, J
    Kruzel, T
    Wojnar, J
    Krawczyk-Kulis, M
    Wylezol, I
    BONE MARROW TRANSPLANTATION, 2004, 33 : S138 - S138
  • [30] The detection of Ph-positive cells by cytogenetic and fish analysis in interferon-treated patients with CML.
    Borovik, CL
    Bittencourt, EAA
    Loghin-Grosso, NS
    Guerra, JC
    Bacal, N
    AMERICAN JOURNAL OF HUMAN GENETICS, 1997, 61 (04) : A361 - A361
12345